Mirati Therapeutics (MRTX) PT Lowered to $100 at Morgan Stanley Ahead of ASCO
Tweet Send to a Friend
Morgan Stanley analyst Michael Ulz lowered the price target on Mirati Therapeutics (NASDAQ: MRTX) to $100.00 (from $140.00) ahead of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
